Mgi Pharma (MM) (NASDAQ:MOGN)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Mgi Pharma (MM) Charts. Click Here for more Mgi Pharma (MM) Charts.](/p.php?pid=staticchart&s=N%5EMOGN&p=8&t=15)
Eisai Co., Ltd. (Tokyo, TSE: 4523) (“Eisai”)
and MGI PHARMA, INC. (NASDAQ: MOGN) (“MGI
PHARMA”) announced today that the Federal
Trade Commission has granted early termination of the statutory waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended (the “HSR Act”),
applicable to the acquisition of MGI PHARMA by Eisai.
As previously announced on December 21, 2007, an indirect wholly-owned
subsidiary of Eisai, Jaguar Acquisition Corp., commenced an all cash
offer to purchase all outstanding shares of the common stock of MGI
PHARMA, including the associated preferred share purchase rights, for
US$41.00 per share, without interest and subject to applicable
withholding of taxes. The offer is scheduled to expire at 12:00 midnight
(New York City time) on January 22, 2008. The grant of early termination
of the waiting period under the HSR Act satisfies one of the conditions
to the offer. The offer is conditioned upon, among other things, at
least a majority of all MGI PHARMA shares outstanding (on a fully
diluted basis) being validly tendered and not withdrawn prior to the
expiration of the offer, and the satisfaction of other customary
conditions.
The terms, conditions and other details of the offer are set forth in
the definitive merger agreement and offering documents filed with the
U.S. Securities and Exchange Commission on December 11, 2007, and
December 21, 2007, as amended.
Important Additional Information Has Been Filed with the Securities
and Exchange Commission (“SEC”)
The tender offer described in this press release has commenced, but this
press release is neither an offer to purchase nor a solicitation of an
offer to sell MGI PHARMA shares or any securities. INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT ON
SCHEDULE TO AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE
14D-9 REGARDING THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. The tender offer statement has been filed by Eisai Co.,
Ltd., Eisai Corporation of North America and Jaguar Acquisition Corp.
with the SEC, and the solicitation/recommendation statement has been
filed by MGI PHARMA, INC. with the SEC. Investors and security holders
may obtain a free copy of these statements and other documents filed by
Eisai Co., Ltd., Eisai Corporation of North America and Jaguar
Acquisition Corp. or MGI PHARMA, INC. with the SEC at the website
maintained by the SEC at www.sec.gov.
The tender offer statement and related materials,
solicitation/recommendation statement, and such other documents may be
obtained for free by directing such requests to Georgeson Inc., the
information agent for the tender offer, at 1-212-440-9800 for banks and
brokers or 1-888-605-7543 for shareholders and all others.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc)
company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines;
gastrointestinal disorders; and integrative oncology, including
oncotherapy and supportive-care treatments. Through a global network of
research facilities, manufacturing sites and marketing affiliates, Eisai
actively participates in all aspects of the worldwide healthcare system.
Eisai forecasts group sales of ¥739 billion
in FY2007. More than 50% of the group sales are derived from businesses
outside of Japan.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai
Co., Ltd. and supports the activities of its operating companies in
North America. These operating companies include: Eisai Research
Institute of Boston, Inc., a discovery operation with strong organic
chemistry capabilities; Morphotek, Inc., a biopharmaceutical company
specializing in the development of therapeutic monoclonal antibodies;
Eisai Medical Research Inc., a clinical development group; Eisai Inc., a
commercial operation with manufacturing and marketing/sales functions;
and Eisai Machinery U.S.A., which markets and maintains pharmaceutical
manufacturing machinery.
About MGI PHARMA
MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and
acute care that acquires, researches, develops, and commercializes
proprietary products that address the unmet needs of patients. MGI
PHARMA markets Aloxi®
(palonosetron hydrochloride) Injection, Dacogen®
(decitabine) for Injection, and Gliadel®
Wafer (polifeprosan 20 with carmustine implant) in the United States.
MGI PHARMA directly markets its products in the U.S. and collaborates
with partners to reach international markets. For more information about
MGI PHARMA, please visit www.mgipharma.com.